iShares Biotechnology ETF $IBB Shares Bought by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. lifted its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 16.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 147,707 shares of the financial services provider’s stock after buying an additional 21,052 shares during the period. Rockefeller Capital Management L.P. owned 0.30% of iShares Biotechnology ETF worth $24,929,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Darwin Wealth Management LLC purchased a new position in shares of iShares Biotechnology ETF during the 2nd quarter worth about $25,000. Basepoint Wealth LLC purchased a new stake in iShares Biotechnology ETF in the fourth quarter valued at approximately $26,000. Cary Street Partners Financial LLC acquired a new position in iShares Biotechnology ETF during the fourth quarter worth approximately $29,000. Copia Wealth Management acquired a new position in iShares Biotechnology ETF during the fourth quarter worth approximately $34,000. Finally, Caitlin John LLC acquired a new position in iShares Biotechnology ETF during the fourth quarter worth approximately $34,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 1.9%

Shares of IBB opened at $177.00 on Tuesday. The stock’s fifty day simple moving average is $170.71 and its 200 day simple moving average is $170.72. iShares Biotechnology ETF has a twelve month low of $123.61 and a twelve month high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Monday, June 15th were issued a $0.0238 dividend. This represents a $0.10 dividend on an annualized basis and a yield of 0.1%. The ex-dividend date was Monday, June 15th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.